Article: Schering-Plough and Novartis Sign Agreement Giving Schering-Plough U.S. Marketing Rights to FORADIL(R) AEROLIZER(R) for Respiratory Disease.

Schering-Plough Corporation and Novartis Pharmaceuticals Corporation, an affiliate of Novartis AG , today announced an agreement giving Schering-Plough exclusive U.S. distribution and marketing rights to Novartis' FORADIL(R) AEROLIZER(R) (formoterol fumarate inhalation powder), a selective, long-acting beta2-agonist indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD), and the acute prevention of exercise-induced bronchospasm.

Under terms of the agreement, Novartis receives an upfront license payment and could receive additional payments upon the achievement of certain milestones. In addition, Schering-Plough will ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!